Analysing the domestic market for influenza vaccines

influenza is the most common infectious disease in the world. Vaccination remains the best available tool to prevent influenza and reduce the risk of serious complications provoked by influenza. Preventive vaccinations can be given free of charge in all state medical organisations where immunisation is carried out within the framework of the National and Regional Calendar of Preventive Vaccinations. Today, the Russian market offers flu vaccines with different active ingredients and trade names. Vaccines provide protection against several strains of influenza virus at once. In the current season for vaccination in Russia are used mainly domestic vaccines, which have differences in valence, antigens, the presence of additives. Purpose of work: marketing analysis of the Russian market of influenza vaccines and assessment of prospects for its development. The paper analyses the domestic market of influenza vaccines; identifies the most popular and sold influenza vaccines; identifies the leading manufacturers in this segment in terms of sales in both monetary and physical terms; analyses the competitive situation in the domestic market of influenza vaccines; formulates conclusions about the state of the domestic market of influenza vaccines and the prospects for its development. Materials and methods. Data from DSM Group and the State Register of Medicines were used as input data for analysing the influenza vaccine market. Results and conclusions: The leading manufacturers of influenza vaccines are the Russian companies MICROGEN NPO, PETROVAX PHARM NPO, FORT. In 2023, their market share amounted to more than 90% of the market in value and volume terms. In the Russian market, the most common vaccines of the Russian company are MICROGEN NPO. There are vaccines from Sanofi and Abbott Laboratories of the foreign vaccines available on the Russian market. MICROGEN NPO is the leader in the hospital segment, PETROVAX PHARM NPO in the retail segment. ABBOTT LABORATORIES is the leader among importers. Today, the Russian market is not experiencing a shortage of influenza vaccines, in addition, there is potential to increase the volume of drug exports to the EAEU countries and abroad.

influenza, influenza vaccine, vaccination, marketing analysis